Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: A rare population of tumor antigen-specific CD4+CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells

Fig. 4

IFN-γ production and in vitro cytotoxicity of TCR-transduced T cells against cancer cells. a Whole PBMC, CD4+ or CD8+ T cells that were transduced with 19305DP-TCR, CD8SP-TCR, or control irrelevant TCR gene were cocultured with A375 and the culture supernatant was harvested at day 1 - day 4. IFN-γ levels in the supernatant were measured by ELISA. b Whole PBMC were transduced with 19305DP-TCR, CD8SP-TCR or control-TCR and tested for cytotoxicity against the indicated melanoma cell lines in a calcein-AM release assay. *p < 0.05 compared with CD8SP. c Cytotoxic activity of isolated CD4+ or CD8+ T cells transduced with 19305DP-TCR or CD8SP-TCR against the same panel of melanoma cell lines in (b) was tested. *p < 0.05 compared with CD8SP-CD4 or CD8SP-CD8, respectively. d A375 and TCR-transduced T cells were cocultured at 1:2 ratio in a 24-well culture plate for 24 h. The cells were harvested with 0.25% trypsin treatment and stained with anti-CD3 antibody followed by FITC annexin V apoptosis detection kit. Annexin V and PI expression on cancer cells gated by FCS/SSC profile and negative CD3 expression were plotted

Back to article page